Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Pharma
Asia
Drug Delivery
Executives
Clinical Data
Vaccines
Special Reports
Trending
COVID-19
Cell & Gene Therapy
Podcasts
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Subscribe
What are you searching for?
Enclose phrases in quotes. Use a + to require a term in results and - to exclude terms.
Example: +water -Europe
Subscribe
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Pharma
Asia
Drug Delivery
Executives
Clinical Data
Vaccines
Special Reports
Trending
COVID-19
Cell & Gene Therapy
Podcasts
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Servier
Pharma
Takeda, Hutchmed hook up on cancer drug for $1.13B
Takeda has gained commercial rights to Hutchmed's cancer drug fruquintinib outside of China for $400M up front, plus $730M in potential milestones.
Kevin Dunleavy
Jan 23, 2023 10:31am
Servier, Taiho's Lonsurf excels in colorectal cancer upgrade
Jan 18, 2023 3:50pm
Rigel's nod for Rezlidhia sets up battle with Servier in AML
Dec 2, 2022 9:57am
Sevier's Tibsovo gets FDA nod in combo with BMS' Vidaza in AML
May 26, 2022 10:02am
A trial win could bless Servier's Tibsovo with a 3rd cancer nod
Dec 11, 2021 7:01am
Servier eyes more deals to beef up oncology business: U.S. CEO
Sep 1, 2021 10:30am
